These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 36165893)

  • 21. Disruption of FDPS/Rac1 axis radiosensitizes pancreatic ductal adenocarcinoma by attenuating DNA damage response and immunosuppressive signalling.
    Seshacharyulu P; Halder S; Nimmakayala R; Rachagani S; Chaudhary S; Atri P; Chirravuri-Venkata R; Ouellette MM; Carmicheal J; Gautam SK; Vengoji R; Wang S; Li S; Smith L; Talmon GA; Klute K; Ly Q; Reames BN; Grem JL; Berim L; Padussis JC; Kaur S; Kumar S; Ponnusamy MP; Jain M; Lin C; Batra SK
    EBioMedicine; 2022 Jan; 75():103772. PubMed ID: 34971971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IRAK4 Signaling Drives Resistance to Checkpoint Immunotherapy in Pancreatic Ductal Adenocarcinoma.
    Somani VK; Zhang D; Dodhiawala PB; Lander VE; Liu X; Kang LI; Chen HP; Knolhoff BL; Li L; Grierson PM; Ruzinova MB; DeNardo DG; Lim KH
    Gastroenterology; 2022 Jun; 162(7):2047-2062. PubMed ID: 35271824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleotide.
    Oweida AJ; Mueller AC; Piper M; Milner D; Van Court B; Bhatia S; Phan A; Bickett T; Jordan K; Proia T; Schulick R; Messersmith WA; Del Chiaro M; Clambey E; Gough MJ; Williams J; Hansen K; Goodman K; Karam SD
    Cancer Immunol Immunother; 2021 Apr; 70(4):989-1000. PubMed ID: 33097963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. C4b-binding protein α-chain enhances antitumor immunity by facilitating the accumulation of tumor-infiltrating lymphocytes in the tumor microenvironment in pancreatic cancer.
    Sasaki K; Takano S; Tomizawa S; Miyahara Y; Furukawa K; Takayashiki T; Kuboki S; Takada M; Ohtsuka M
    J Exp Clin Cancer Res; 2021 Jun; 40(1):212. PubMed ID: 34167573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nano-Econazole Enhanced PD-L1 Checkpoint Blockade for Synergistic Antitumor Immunotherapy against Pancreatic Ductal Adenocarcinoma.
    Li Q; Qin S; Tian H; Liu R; Qiao L; Liu S; Li B; Yang M; Shi J; Nice EC; Li J; Lang T; Huang C
    Small; 2023 Jun; 19(23):e2207201. PubMed ID: 36899444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer.
    Zhao J; Xiao Z; Li T; Chen H; Yuan Y; Wang YA; Hsiao CH; Chow DS; Overwijk WW; Li C
    ACS Nano; 2018 Oct; 12(10):9881-9893. PubMed ID: 30231203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Receptor-interacting Protein Kinase 2 Is an Immunotherapy Target in Pancreatic Cancer.
    Sang W; Zhou Y; Chen H; Yu C; Dai L; Liu Z; Chen L; Fang Y; Ma P; Wu X; Kong H; Liao W; Jiang H; Qian J; Wang D; Liu YH
    Cancer Discov; 2024 Feb; 14(2):326-347. PubMed ID: 37824278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
    Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy.
    Blair AB; Wang J; Davelaar J; Baker A; Li K; Niu N; Wang J; Shao Y; Funes V; Li P; Pachter JA; Maneval DC; Dezem F; Plummer J; Chan KS; Gong J; Hendifar AE; Pandol SJ; Burkhart R; Zhang Y; Zheng L; Osipov A
    Gastroenterology; 2022 Nov; 163(5):1267-1280.e7. PubMed ID: 35718227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15
    Dominguez CX; Müller S; Keerthivasan S; Koeppen H; Hung J; Gierke S; Breart B; Foreman O; Bainbridge TW; Castiglioni A; Senbabaoglu Y; Modrusan Z; Liang Y; Junttila MR; Klijn C; Bourgon R; Turley SJ
    Cancer Discov; 2020 Feb; 10(2):232-253. PubMed ID: 31699795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
    Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
    Front Immunol; 2018; 9():1878. PubMed ID: 30158932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Injectable hybrid hydrogels enable enhanced combination chemotherapy and roused anti-tumor immunity in the synergistic treatment of pancreatic ductal adenocarcinoma.
    Zhou H; Wang W; Cai Z; Jia ZY; Li YY; He W; Li C; Zhang BL
    J Nanobiotechnology; 2024 Jun; 22(1):353. PubMed ID: 38902759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
    Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells.
    Zhang J; He DH; Zajac-Kaye M; Hochwald SN
    Cell Cycle; 2014; 13(19):3143-9. PubMed ID: 25486573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis.
    Verma A; Wang H; Manavathi B; Fok JY; Mann AP; Kumar R; Mehta K
    Cancer Res; 2006 Nov; 66(21):10525-33. PubMed ID: 17079475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD200 promotes immunosuppression in the pancreatic tumor microenvironment.
    Choueiry F; Torok M; Shakya R; Agrawal K; Deems A; Benner B; Hinton A; Shaffer J; Blaser BW; Noonan AM; Williams TM; Dillhoff M; Conwell DL; Hart PA; Cruz-Monserrate Z; Bai XF; Carson WE; Mace TA
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Precise Photodynamic Therapy by Midkine Nanobody-Engineered Nanoparticles Remodels the Microenvironment of Pancreatic Ductal Adenocarcinoma and Potentiates the Immunotherapy.
    Qu C; Yuan H; Tian M; Zhang X; Xia P; Shi G; Hou R; Li J; Jiang H; Yang Z; Chen T; Li Z; Wang J; Yuan Y
    ACS Nano; 2024 Feb; 18(5):4019-4037. PubMed ID: 38253029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
    Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.